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Abstract 
Background 
Human induced pluripotent stem cells (hiPSCs), which are derived by introducing 
reprogramming factors, such as OCT4, SOX2, KLF4, and MYC (OSKM), into somatic 
cells, have revolutionized not only stem cell biology but also clinical medicine. In the 
clinic, various types of cells, including monocytes, adipocytes, and fibroblasts, can be 
used for hiPSC generation, which suggests that there may be a common reprogramming 
route regardless of somatic cell type. A recent study suggests that the maturation step, 
the reprogramming phase in which pluripotency genes begin to be expressed, is the 
main roadblock for reprogramming hiPSCs from human dermal fibroblasts (HDFs). 
Therefore, I investigated whether a common reprogramming route exists across various 
human cell types and whether the maturation step is the major barrier to reprogramming 
in various cell types. 
Results 
To identify common reprogramming routes for hiPSC generation, I analyzed time-
course microarrays containing gene expression data from 5 human somatic cell lines, 
including HDFs (Human Dermal Fibroblasts), ASCs (Adipose-derived Stem Cells), 
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HAs (Human Astrocytes), NHBEs (Normal Human Bronchial Epithelial cells) and 
PrECs (Prostate Epithelial Cells). I identified 3615 genes that underwent dynamic 
expression changes during the reprogramming process. I evaluated the overall similarity 
between samples using principal component analysis and hierarchical clustering. The 
results indicated that there were 3 distinct transcriptomic phases following induction of 
OSKM reprogramming factors: an early phase between days 0 and 3, a mid phase 
between days 7 and 15, and a late phase encompassing days 20 and on. The greatest 
phase-to-phase differences were found between the mid and late phases. To study the 
molecular events that take place during reprogramming, I categorized the 3615 genes 
into 5 separate groups according to their gene expression patterns during 
reprogramming. Functional annotation of the gene lists in each group revealed common 
reprogramming events among the 5 cell types: mesenchymal-epithelial transition 
between days 0 and 3, transient up-regulation of epidermis-related genes between days 
7 and 15, and up-regulation of cell cycle and pluripotency genes beginning at day 20. 
Furthermore, because TFs can regulate cell fate by controlling target gene expression, I 
focused on transcription factor activity at each time point during the reprogramming 
process and identified a major transition between days 15 and 20, regardless of cell 
type. Given that previous studies have considered day 15 to be the beginning of the 
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maturation phase for HDF reprogramming, my results imply that the maturation step is 
a major roadblock in the reprogramming process across multiple cell types. 
Conclusions 
This study suggests that the human cellular reprogramming process of multiple different 
cell types can be separated into 3 different phases following OSKM induction: an early 
phase between days 0 and 3, a mid phase between days 7 and 15, and a late phase 
beginning at day 20. As the late phase exhibited the greatest dissimilarity based on 
transcriptome and transcription factor activity analysis, the transition from the mid 
phase to the late phase is likely to be a common major roadblock during human cellular 
reprogramming. A better understanding of the molecular mechanisms of this transition 
would enhance reprogramming efficiency for hiPSC generation. 
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Chapter 1: Introduction 
1-1: Overview of human iPSCs and their relation to Human 
Biology 
The human body is estimated to contain approximately 37 trillion cells (Bianconi et al., 
2013) and renewal of these cells is essential to maintain a stable internal environment. 
Although the human body is able to replace injured skin and vasculature, entire organs 
cannot be regenerated. Regenerative medicine aims to compensate for damaged organs 
by replacing them with healthy cells, tissues, and organs from patients. Current 
regenerative medicine techniques involve organ transplantations and artificial internal 
organs, however these methods could present significant problems, including transplant 
rejection and donor shortages. 
Along with the development of stem cell biology, regenerative medicine using stem 
cells (including somatic stem cells and embryonic stem cells (ESCs)) has attracted 
attention as a solution to these problems. Mouse and human ESCs were first generated 
in 1981 and 1998, respectively (Evans and Kaufman, 1981; Martin, 1981; Thomson et 
al., 1998). Since ESCs theoretically are able to differentiate into all cell types in the 
human body, transplantation of ESC-derived somatic cells is expected to be medically 
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valuable for the treatment of various diseases and trauma, including diabetes, 
Parkinson's disease, and spinal cord injury. However, because it is impossible to 
establish ESCs and ESC-derived somatic cells with the same genetic information as that 
of the recipient, administration of immunosuppressive drugs is necessary to avoid 
transplant rejection. In addition, ethical problems remain, as the establishment of ESCs 
involves the sacrifice of fertilized eggs. 
One way to solve these problems is to generate pluripotent stem cells, such as ESCs, 
from the patient's own cells. The phenomenon whereby differentiated cells, including 
skin cells, acquire ESC-like pluripotency is called reprogramming, and several methods 
of establishing this pluripotency have previously been reported. 
Representative pluripotency-establishing methods include nuclear transplantation and 
cell fusion. Nuclear transplantation involves the removal of the nucleus of an 
unfertilized egg and the subsequent transplantation of the nucleus of a somatic cell into 
the enucleated unfertilized egg. Since the nuclear transplanted fertilized egg contains a 
somatic cell-derived nucleus, it has the genetic information of the somatic cell. Thus, it 
is possible to generate stem cells containing a recipient’s genetic information. Dolly, the 
cloned sheep, was generated in 1997 by transplanting the nucleus of a mammary gland 
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cell into an enucleated unfertilized egg (Wilmut et al., 1997). Meanwhile, cell fusion is 
a phenomenon whereby a stimulated ESC is fused with a somatic cell; the resulting 
cells display the properties of ESCs in both mice and humans (Cowan et al., 2005; Tada 
et al., 2001). However, since pluripotent cells obtained by cell fusion contain ESC-
derived genetic information, transplantation of these cells could cause rejection by the 
recipient. To solve this problem, research aiming to remove ESC-derived genetic 
information is actively being conducted (Matsumura et al., 2007; Pralong et al., 2005). 
Although the biotechnology has been developed to the point where both nuclear 
transplantation and cell fusion technology can successfully generate pluripotent stem 
cells, ethical problems remain because these techniques require unfertilized eggs and 
ESCs, respectively.  
Meanwhile, somatic stem cells can be collected directly from patients, thus no ethical 
problems or risk of transplant rejection limit their clinical application. However, they 
are inferior to ESCs in terms of differentiation and proliferation ability. Typical 
examples of somatic stem cells include hematopoietic stem cells (HSCs) in the bone 
marrow and umbilical cord blood. HSCs can differentiate into various cells of the 
circulatory system. In addition, mesenchymal stem cells residing in the bone marrow 
can differentiate into bone, cartilage and adipose cells. Although somatic stem cells 
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have certain advantages, it is difficult to prepare a large enough number of cells because 
their proliferative capacity is limited and it can be difficult to collect enough of the 
somatic stem cells by biopsy. Therefore, there is a need to establish patient-derived 
pluripotent stem cells that have neither rejection nor ethical problems but display the 
high proliferation and pluripotency characteristic of ESCs. 
Mouse and human induced pluripotent stem cells (iPSCs) were first established in 2006 
and 2007, respectively (Takahashi and Yamanaka, 2006; Takahashi et al., 2007; Yu et 
al., 2007). iPSCs can be generated from somatic cells via induction of four transcription 
factors (Oct3/4, Sox2, Klf4, c-Myc, called OSKM). OSKM-induced somatic cells 
change their morphology and acquire ESC-like pluripotency. The discovery of iPSCs 
has revolutionized not only stem cell biology but also clinical medicine. Since human 
iPSCs (hiPSCs) were first established in 2007 (Takahashi et al., 2007; Yu et al., 2007), 
they have enabled new strategies for regenerative medicine, research into disease 
mechanisms, and an understanding of cell fate. In particular, the differentiation of 
hiPSCs into target cell types plays a pivotal role in accelerating clinical applications for 
the treatment of diseases with patient-derived hiPSCs. Current transplantation methods 
require cells or tissues from a donor; however, hiPSCs do not require any sacrifice. 
Thus, hiPSCs can also overcome ethical problems of transplantation. 
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The establishment of hiPSCs has been reported by various research groups. The first 
major somatic cells used to generate hiPSCs were newborn fibroblasts and adult skin 
cells (Lowry et al., 2008; Park et al., 2008; Takahashi et al., 2007; Yu et al., 2007). 
Although fibroblasts can be relatively easily harvested by biopsy, hiPSCs sometimes 
cannot be established from these cells due to their decreased proliferative capacity and 
cellular senescence (Park et al., 2008). Therefore, researchers have aimed to generate 
hiPSCs from other somatic cells. Currently, hiPSCs have been derived from various 
tissues, including lung-derived fibroblasts (Park et al., 2008; Yu et al., 2007), 
adipocytes (Aoki et al., 2010), epithelial cells (Aasen et al., 2008; Ono et al., 2012; 
Zhou et al., 2012) and peripheral blood cells (Loh et al., 2009; Staerk et al., 2010). 
However, one drawback of hiPSCs is that it takes approximately 1-2 months to generate 
patient-derived hiPSCs. Although some chronic diseases, such as Parkinson’s disease 
and age-related macular degeneration, can be treated with patient-derived hiPSCs, 
clinical treatment of acute diseases, including acute ischemic cardiomyopathy and 
cerebral stroke, is difficult due to the time required for reprogramming. To overcome 
this problem, the iPSC Bank has been established (McKernan and Watt, 2013). 
Allotransplantation of hiPSCs is possible when the types of human leukocyte antigen 
(HLA) are the same between the recipient and the donor. Therefore, once hiPSCs with 
10 
 
various HLA types are stocked, these cells could be readily available for transplantation. 
In Japan, the world’s first allotransplantation of hiPSCs to treat age-related macular 
degeneration was conducted in 2017 using a stockpile of hiPSCs at Kyoto University. 
The iPSC Bank could make the application of hiPSCs for regenerative medicine rapid, 
safe, and cost-friendly. However, a recent study indicated that approximately 30% of 
stocked hiPSCs still might be rejected by natural killer T cells (Ichise et al., 2017). 
Therefore, the generation of patient-specific iPSCs remains of the utmost importance. 
This will require a better understanding of reprogramming mechanisms leading to the 
establishment of an optimal method for preparing hiPSCs and an improvement in 
production efficiency. 
1-2: Mechanisms of reprogramming somatic cells into iPSCs 
Compared to the progress made in the clinic, the understanding of the molecular 
mechanisms underlying cellular reprogramming is significantly lagging. However, 
some mechanistic insights have been acquired and I will discuss them here. 
Previous studies involving time-course gene expression analyses during reprogramming 
were mostly performed using mouse embryonic fibroblasts (MEFs). These studies 
suggested that the progression of reprogramming could be broadly divided into three 
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phases: initiation, maturation, and stabilization (David and Polo, 2014; Golipour et al., 
2012; Samavarchi-Tehrani et al., 2010). Cellular reprogramming begins with the 
mesenchymal-to-epithelial transition (MET), one of the hallmark events of initiation. 
MET occurs within a few days of OSKM induction (David and Polo, 2014; Li et al., 
2010). It is well known that induction of MET initiates iPSC reprogramming and that 
inhibition of MET suppresses reprogramming. Among the OSKM factors, Sox2 
suppresses expression of Snail, an EMT inducer (Liu et al., 2013), and Klf4 induces 
expression of E-cadherin, thus promoting MET (Li et al., 2010). In addition, Glis1, a 
Gli-like transcription factor, can substitute for c-Myc and can enhance the expression of 
forkhead box A2 (Foxa2), which inhibits epithelial-mesenchymal transition (EMT). 
Thus, Glis1 might stimulate somatic cell reprogramming by promoting MET (Maekawa 
et al., 2011). In addition, TGF-β signaling enhances EMT by activating EMT-related 
genes, mediating the disassembly of junctional complexes, and reorganizing the cell 
cytoskeleton (Thiery and Sleeman, 2006). Several groups have demonstrated the ability 
of TGF-β inhibition to enhance the initiation stage of somatic cell reprogramming in 
both mice (Maherali and Hochedlinger, 2009; Shi et al., 2008) and humans (Lin et al., 
2009). This observation is supported by the finding that addition of recombinant TGF-β 
abrogates iPSC formation (Lin et al., 2009), likely as a result of the EMT-inducing 
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action of TGF-β signaling, which then prevents MET. Furthermore, various TGF-β 
inhibitors have been used to promote reprogramming, including A-83-01 (Li et al., 
2010; Zhu et al., 2010), E616452 (also known as RepSox) (Hou et al., 2013; Maherali 
and Hochedlinger, 2009) and SB431542 (Lin et al., 2009). Together, these results 
indicate that MET plays a critical role in early cellular reprogramming. 
Maturation is described as the phase during which pluripotency genes, such as 
endogenous Oct4 (not exogenously induced Oct4), Nanog, and Sall4, begin to be 
expressed in an exogenous OSKM-dependent manner (David and Polo, 2014; Golipour 
et al., 2012; Samavarchi-Tehrani et al., 2010). This intermediate phase can play 
important roles in acquiring stable pluripotency. In the maturation phase, several 
pluripotency-related genes are gradually expressed. Fbxo15, Sall4, and endogenous 
Oct4 are the first markers to be detected; this is followed by the expression of Nanog 
and Esrrb in mouse iPSCs (Buganim et al., 2012; David and Polo, 2014; Golipour et al., 
2012; Polo et al., 2012). Although the underlying molecular mechanisms of maturation 
largely remain unknown, maturation genes are known to be good markers of 
reprogramming. In addition, the epigenetic barriers involved in maturation have actively 
been studied. One study showed that over-expression of C/EBPα leads to the expression 
of Tet2, which plays a key role in active DNA demethylation and greatly enhances 
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reprogramming efficiency in mouse B cells (Di Stefano et al., 2014). Furthermore, the 
expression pattern of pluripotency genes during B cell reprogramming was highly 
correlated to the pattern observed during MEF reprogramming (Di Stefano et al., 2014). 
This study suggested that the maturation process was conserved across cell types. 
Finally, the cells that are able to transition to the stabilization phase gain transgene-
independent stem cell properties through stable expression of pluripotency genes and 
become iPSCs (Brambrink et al., 2008; David and Polo, 2014; Golipour et al., 2012; 
Maekawa et al., 2011; Samavarchi-Tehrani et al., 2010).  
Compared to reprogramming systems in mouse cells, some hiPSCs reprogramming 
events differ slightly in terms of characteristics and timing, although hiPSCs can be 
generated by the induction of the same transcription factors (Teshigawara et al., 2017). 
For example, MET occurs relatively later in the human reprogramming process, when 
exogenous OSKM becomes suppressed and endogenous OCT4 starts to appear 
(Teshigawara et al., 2016). In addition, the pluripotent states are different in human and 
mouse iPSCs, called 'primed' and 'naïve', respectively (Chia et al., 2010; Hanna et al., 
2010). Naïve stem cells, such as mouse ESCs, have the ability to contribute to chimera 
formation, but primed stem cells, such as mouse epiblast stem cells, do not have this 
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ability. hiPSC colony morphology and gene expression profiles are more similar to 
those of mouse epiblast stem cells (Nichols and Smith, 2009). These differences 
between mouse and human iPSC generation suggest that there might be some distinct 
reprogramming events. Because the understanding of the human cell reprogramming 
process is still limited relative to that of mice, it is of the utmost importance to explore 
the reprogramming process in human cells as comprehensively as it has been studied in 
mouse cells. 
Although current insights into the cellular reprogramming of hiPSCs are confined to 
fibroblasts, hiPSCs have been established from multiple somatic cell types, including 
dermal fibroblasts (Lowry et al., 2008; Park et al., 2008; Takahashi et al., 2007; Yu et 
al., 2007), adipocytes (Aoki et al., 2010), epithelial cells (Aasen et al., 2008; Ono et al., 
2012; Zhou et al., 2012) and peripheral blood cells (Loh et al., 2009)). Notably, a recent 
study reported that all five types of OSKM-induced human somatic cells (fibroblasts, 
adipose-derived stem cells, astrocytes, bronchial epithelial cells and prostate epithelial 
cells) exhibited transiently similar transcriptome profiles that resemble a primitive 
streak (Takahashi et al., 2014). The facts that hiPSCs can be generated from various 
types of cells and that different types of reprogramming cells have transiently similar 
gene expression profiles suggest that a common hiPSC reprogramming pathway might 
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exist across multiple cell types. Furthermore, a recent study indicated that the 
maturation stage, which occurs between days 7 and 15 following OSKM transduction in 
human dermal fibroblasts (HDFs) and when the expression of pluripotency genes, such 
as OCT4, NANOG, and SALL4, begins, is a major roadblock in the reprogramming 
process (Tanabe et al., 2013). Based on these results, I aimed to detect a common 
reprogramming process in various human cell types and to evaluate whether maturation 
is a common roadblock in multiple cell types.  
For this purpose, I extracted 3615 dynamically expressed genes from time course gene 
expression data across five different human somatic cell types undergoing 
reprogramming (Takahashi et al., 2014). Next, I divided these genes into five clusters 
according to their gene expression patterns and functionally characterized each cluster. 
Lastly, I inferred transcription factor (TF) activity during the reprogramming process. 
The results obtained in this work suggested that reprogramming was consistently driven 
through three phases in all five-cell types, including fibroblasts, adipose-derived stem 
cells, astrocytes, bronchial epithelial cells and prostate epithelial cells. Furthermore, 
maturation is suggested to be the common roadblock in reprogramming in all five cell 
types.  
16 
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Chapter 2: Materials and Methods 
2-1: Microarray data  
To identify conserved genes with dynamic expression from various reprogrammed 
human cell types, I used a dataset from the Gene Expression Omnibus under the 
accession number GSE50206 
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE50206) (Takahashi et al., 
2014). This dataset contains time-course microarray data of cellular reprogramming in 
five human somatic cell types - HDFs (Human Dermal Fibroblasts), ASCs (Adipose-
derived Stem Cells), HAs (Human Astrocytes), NHBEs (Normal Human Bronchial 
Epithelial cells) and PrECs (Prostate Epithelial Cells) - and two stem cells types - 
hiPSCs and human ESCs (hESCs) (Figure 1a). 
2-2: Data processing 
Raw microarray signals (gProcessedSignal) were processed using log2 transformation 
and quantile normalization to compare samples using the following statistical analysis. 
Log-transformed signals were used so that signal distributions were close to a normal 
distribution because many statistical methods are available for signals that follow a 
normal distribution (Quackenbush, 2002). In addition, quantile normalization was used 
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to make the signals comparable across samples. I used the limma package for quantile 
normalization in R using Bioconductor (Ritchie et al., 2015).  
2-3: Selection of dynamically expressed genes 
To identify genes that were dynamically expressed across all cell types during the 
reprogramming process, I used the maSigPro package (Conesa et al., 2006) on each cell 
type and screened genes that showed significant differences among all five cell types 
(P-value < 0.01, FDR < 0.05, R2 > 0.6). In detail, I first fitted a regression model to 
discover probe sets with significant differential expression during reprogramming. The 
null hypothesis was that the means of the microarray signals at each time point were all 
equal. Significant genes were selected using the P-value associated with the F-Statistic 
in the linear regression model. This P-value was corrected for multiple comparisons by 
applying the linear step-up false discovery rate (FDR) procedure (Reiner et al., 2003). 
After identifying models with statistically significant genes, the regression coefficients 
were used to identify the conditions for which genes showed statistically significant 
changes during reprogramming. To do this, maSigPro fitted three-dimensional 
polynomial equations to explain each gene expression patterns. Lastly, I extracted genes 
whose R-squared value in the regression model was greater than 0.6. The R-squared 
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value indicated how well a cubic equation was fitted to the gene expression patterns. By 
using the R-squared value, I identified genes with expression patterns that were well 
fitted by a cubic equation and discarded genes and outliers with irregular gene 
expression profiles. Consequently, this filtration process yielded 3615 extracted genes 
(Figure. 1b). When multiple probes annotated the same genes, the probe signals were 
averaged. 
2-4: Transcription factor activity inference 
After extracting 3615 genes from all five cell types undergoing reprogramming, I 
applied the CoRegNet package (Nicolle et al., 2015) to infer transcription factor (TF) 
activity during the reprogramming process. The CoRegNet infers cooperative TF 
networks and scores the influence of specific TFs with the h-LICORN (hybrid-learning 
cooperative regulation networks) algorithm by using TF and target gene expression 
profiles (Figure 1b) (Chebil et al., 2014; Elati et al., 2007).  
Specifically, the temporal gene expression data included 5 samples and 100 genes. 
CoRegNet categorized these genes into TFs and non-TFs using a list of 2020 human 
transcription factors from the FANTOM consortium (Ravasi et al., 2010). Let us 
suppose that there are 3 TFs and 97 non-TFs. CoRegNet converts gene expression 
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levels to ternary values: −1 (under-expressed), 0 (no change) or 1 (over-expressed). For 
instance, the following table details example gene expression data, including genes 1-
100 across 5 samples.  
 
sample1 sample2 sample3 sample4 sample5 
gene1 4.085179 2.502032 5.434952 6.783058 3.313376 
gene2 3.453015 3.16476 2.911037 2.938859 3.027613 
... 
     
gene100 7.478364 8.680674 6.118773 6.257344 6.397665 
Then, each gene expression signal is normalized (raw signal - average signal).  
 
sample1 sample2 sample3 sample4 sample5 
gene1 -0.33854 -1.92168737 1.0112323 2.359339 -1.11034368 
gene2 0.3539582 0.06570359 -0.1880199 -0.160198 -0.07144386 
... 
     
gene100 0.4917998 1.69410985  -0.8677907 -0.7292201 -0.58889888 
 
The standard deviation (SD) of all normalized signals is 1.087876. Then, discrete values 
are obtained by defining the normalized values as 1 (if signal > SD), -1 (if signal < -
SD), or 0 (all other cases).     
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sample1 sample2 sample3 sample4 sample5 
gene1 0 -1 0 1 -1 
gene2 -1 0 1 0 -1 
... 
     
gene100 0 1 0 0 0 
 
After discretization, CoRegNet generates 2 tables based on discrete TF expression 
values. Here is an example table that lists discretized TF expression values. 
 
sample1 sample2 sample3 
TF1 -1 0 0 
TF2 0 1 1 
TF3 -1 0 1 
 
CoRegNet generates the following 2 tables. The left table contains the values 1 (discrete 
values equal to 1) and 0 (all other values). The right table contains the values -1 
(discrete values equal to -1) and 0 (all other values). 
 
sample1 sample2 sample3 
  
sample1 sample2 sample3 
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TF1 0 0 0 
 
TF1 -1 0 0 
TF2 0 1 1 
 
TF2 0 0 0 
TF3 0 0 1 
 
TF3 -1 0 0 
 
To identify the non-TF genes that could be regulated by TFs, CoRegNet uses 
association analysis. For instance, when extracting samples where the expression value 
of non-TF1 is not equal to 0, associations can be identified as follows. 
 
sample1 sample2 sample3 sample4 sample5 
non-TF1 1 1 0 -1 -1 
TF1 -1 0 0 0 1 
TF2 0 1 1 -1 0 
TF3 -1 0 1 0 1 
 
sample1 {TF1-TF3 (rep)} 
sample2 {TF2 (act)} 
sample4 {TF2 (act)} 
sample5 {TF1-TF3 (rep)} 
 
{TF (act)} indicates that the discretized expression of TFs is the same as the expression 
of non-TFs. {TF (rep)} indicates that the discretized expression of TFs is not equal to 
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the expression of non-TFs. Support values are calculated as (number of rules)/(number 
of samples), which indicates the frequency of the rules. When calculating each support, 
{TF1 - TF3 (rep)} = 2(the numbers of rules)/4 (the numbers of samples) = 0.5 and {TF2 
(act)} = 2/4 = 0.5. When the threshold of support is set to 0.33, both {TF1 - TF3 (rep)} 
and {TF2 (act)} can be identified as the candidate TFs whose expression levels are 
positively or negatively correlated with the expression of non-TF1.  
Finally, CoRegNet scores the TF influence. The TF influence is defined as a t-statistic, 
which indicates the ratio of the sum of the gene expression values of non-TFs in 2 
groups (act and rep). For example, when the expression levels of non-TF1 through non-
TF5 and their TFs are positively (act) or negatively (rep) correlated, as displayed in the 
following first table, the influence of each TF in each sample can be calculated as 
shown in the following second and third tables.  
 
expression of  
sample1 
expression of 
sample2 
act rep 
non-TF1 10 30 {TF2} {TF1-TF3} 
non-TF2 20 5 {TF1} {TF2} 
non-TF3 30 10 {TF2-TF3} {TF2} 
non-TF4 40 30 {TF1} {TF3} 
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non-TF5 50 70 {TF3} {TF1} 
 
 
sample1 act sample1 rep sample1 
t-statistics (influence) 
{TF1} 20 (non-TF2),  
40 (non-TF4) 
10 (non-TF1),  
50 (non-TF5) 
0 
{TF2} 10 (non-TF1),  
30 (non-TF3) 
20 (non-TF2),  
30 (non-TF3) 
-0.44721 
{TF3} 30 (non-TF3),  
50 (non-TF5) 
10 (non-TF1),  
40 (non-TF4) 
0.83205 
 
 
sample2 act sample2 rep sample2 
t-statistics (influence) 
{TF1} 5 (non-TF2),  
30 (non-TF4) 
30 (non-TF1),  
70 (non-TF5) 
-1.378 
{TF2} 30 (non-TF1),  
10 (non-TF3) 
5 (non-TF2),  
10 (non-TF3) 
1.2127 
{TF3} 10 (non-TF3),  
70 (non-TF5) 
30 (non-TF1),  
30 (non-TF4) 
0.33333 
 
For instance, the example indicates that the expression of TF1 in sample1 is positively 
correlated to non-TF2 and non-TF4 and that the gene expression levels of non-TF2 and 
non-TF4 are 20 and 40, respectively. On the other hand, the expression of TF1 in 
sample1 is negatively correlated with that of non-TF1 and non-TF5, and the gene 
expression levels of non-TF1 and non-TF5 are 10 and 50, respectively. The t-test 
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(Welch's t-test) of these 2 groups ({20, 40} and {10, 50}) reports that the t-statistic 
equals 0. This suggests that TF1 in sample1 does not play a role in the expression of 
non-TFs because the positively and negatively correlated genes have the almost same 
expression values. 
 
sample1 act sample1 rep sample1 
t-statistics (influence) 
{TF1} 20 (non-TF2),  
40 (non-TF4) 
10 (non-TF1),  
50 (non-TF5) 
0 
The influence of TF1 in sample2 is -1.378. This means that sample2 displays greater 
expression of genes that are negatively correlated with TF1.  
 
sample2 act sample2 rep sample2 
t-statistics (influence) 
{TF1} 5 (non-TF2),  
30 (non-TF4) 
30 (non-TF1),  
70 (non-TF5) 
-1.378 
 
In addition, the significance of these pairs of TFs and non-TFs was tested using Fisher’s 
exact test to examine whether these TFs, such as {TF1} and {TF1-TF3}, have more 
possible target genes than expected by chance (false discovery rate < 0.01 using the 
Benjamini-Hochberg procedure (Reiner et al., 2003)). Consequently, I identified 71 TFs 
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that undergo temporal changes in expression during reprogramming and have more 
possible target genes than expected by chance. 
2-5: Principal component analysis (PCA) and Hierarchical 
Clustering Analysis (HCA) 
Microarray data have various variables, namely the expression values of each gene in 
each sample. For example, the GPL14550 microarray platform that I used in this study 
contains 22062 genes, which means that each sample has 22062 variables. PCA is a 
method that can be used to summarize 22062 variables using just 2 or 3 variables and 
enables the visualization of similarities between samples in 2 dimensional plots. PCA 
constructs new X1, X2 … X22062 axes (principal component 1; PC1 and principal 
component 2; PC2 … principal component 22062; PC22062) that summarize the 22062 
variables. The new X1 axis is the line that maximizes the variation across variables. The 
new X2 axis is the line that intersects the X1 axis at a right angle. In PCA, the 
information content is defined by the variance of the data. When setting the total sum of 
variances of the data on the X1, X2 … X22062 axes equal to 100, the X1 axis (PC1) contains 
the 'variance of X1/100' information content and the X2 axis (PC2) contains the 'variance 
of X2/100' information content. This indicates the amount of information retained by 
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using the X1 and X2 axes. Finally, PCA enables the location of each sample to be 
displayed as a 2 dimensional plot by using the X1 axis (PC1) and the X2 axis (PC2) and 
the coordinate point of a 2 dimensional plot indicates the similarities between samples 
(Ringnér, 2008; Yeung and Ruzzo, 2001).  
HCA is another method used to illustrate the similarities between samples. HCA 
generates a distance matrix by using all 22062 gene expression values and makes a 
cluster by calculating the distance between each sample. In contrast to PCA, HCA uses 
all gene information, thus it is better able to quantitatively compare each sample. 
However, there are many methods that can be used to calculate a distance matrix, 
including Euclidean distance, cosine similarity, Pearson's correlation and clustering 
using the group average method, complete linkage method, and Ward's method. 
Because the results of HCA are highly dependent on the methods, HCA is not a robust 
clustering method (Sturn et al., 2002). 
2-6: Pathway, Gene Ontology (GO), and Protein-protein 
Interaction (PPI) Enrichment Analysis 
For functional annotation of gene sets, I used Metascape (http://metascape.org) to 
identify the top 10 clusters with the representative Reactome and GO Biological 
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Processes (Tripathi et al., 2015) enriched terms. The PPI network was constructed using 
the BioGRID database (Chatr-Aryamontri et al., 2017; Stark et al., 2006). BioGRID 
contains over 200,000 unique PPI and is both well maintained and frequently updated. 
From the reported PPIs, I selected PPIs that consisted of more than four proteins. 
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Figure 1a: Explanation of microarray samples 
Microarray data used in this study were obtained from GSE50206 (Takahashi et al., 
2014) and included reprogramming information from five human somatic cells and two 
stem cells. The majority of the data consists of 3 biological replicates, though ASC Day 
20 and PrEC Day 28 have no replicates, PrEC Day 15 has 2 replicates, and HA Day 7 
and NHBE Day 7 have 4 replicates.  
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Figure 1b: Experimental workflow.  
(a) NANOG and GAPDH were typical examples of dynamically expressed and 
statically expressed genes, respectively, during reprogramming. The filtration method 
extracted NANOG and eliminated GAPDH. maSigPro, an R package, extracts genes 
that undergo temporal expression changes during reprogramming. (b) CoRegNet, an R 
package, identifies transcription factors that may regulate more genes than predicted by 
random selection. The main parameters are indicated in parentheses (See a detailed 
description in the Methods section). 
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Chapter 3: Results 
3-1: Three distinct transcriptomic states exist during cellular 
reprogramming in various cell types. 
To analyze similarities among the cellular transcription profiles of each sample at each 
time point during reprogramming, I performed principal component analysis (PCA) and 
hierarchical clustering analysis (HCA) on 3615 genes. When I compared the extracted 
genes with all 22062 genes in the microarray, the reprogramming trajectory could be 
easily traced by the extracted genes in the PCA (Figure 2a, c), supporting the technical 
validation of gene extraction filtering methods. Furthermore, the gene filtering system 
successfully increased the contribution ratio of principal component 1 (PC1) and 
principal component 2 (PC2) from 26.07% and 11.87% to 40.53% and 17.48%, 
respectively (Figure 2a, c).  
According to the PCA and HCA results, the transcriptome evident during cellular 
reprogramming could be broadly divided into three groups: an early phase between days 
0 and 3, a mid phase between days 7 and 15, and a late phase beginning at day 20 
(Figure 2a, b). Although human astrocytes at day 15 following OSKM induction (HA 
d15) were clustered within the late phase, this is consistent with a previous report that 
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human astrocytes can be induced into iPSCs in a highly efficient manner (Ruiz et al., 
2010). Notably, the results indicated that all reprogramming cell types exhibited 
uniformly greater dissimilarities between the mid and late phases than between the early 
and mid phase (Figure 2a, b). 
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Figure 2a: Principal component analysis of each sample using 3615 dynamically 
expressed genes indicated 3 distinct phases with a highly dissimilar late phase.  
Each cell type was colored as follows: HDF (blue), ASC (green), HA (orange), NHBE 
(pink), PrEC (purple), hiPSC (red), and hESC (red). The numbers indicate the number 
of days between OSKM induction and RNA collection. The early, mid phase, and late 
phases are labeled in translucent blue, green, and red, respectively. PC stands for 
Principal Component and the numbers in parentheses indicate the percentage of 
information content. The information content of PCA is expressed as a variance. Thus, 
PC1 contains 40.53% of the total data variance. Considering that the PC1 axis has the 
largest amount of information, the coordinate points of each sample in the early and mid 
phasemid phases are located at almost the same position, however the points of samples 
in the late phase are clearly separated from the points in the early and mid phase. This 
suggested that samples in the late phase have the greatest transcriptomic dissimilarity.  
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Figure 2b: Hierarchical cluster analysis of each sample using 3615 dynamically 
expressed genes also indicated 3 distinct phases and a highly dissimilar late phase.  
The early, mid phase, and late phases are labeled in translucent blue, green, and red, 
respectively. The Y-axis indicates the degree of distance between each cluster.  
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Figure 2c: Principal component analysis of each sample using all 22062 genes in 
the GPL14550 microarray platform also showed 3 distinct phases and the 
dissimilarity of the late phase.  
Each cell type was colored as follows: HDF (blue), ASC (green), HA (orange), NHBE 
(pink), PrEC (purple), hiPSC (red), and hESC (red). The numbers indicate the number 
of days between OSKM induction and RNA collection. The early, mid phase, and late 
phases are labeled in translucent blue, green, and red, respectively. 
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Figure 2d: Hierarchical cluster analysis of each sample using all 22062 genes in the 
GPL14550 microarray platform showed the dissimilarity of the late phase.  
The early, mid phase, and late phases are labeled in translucent blue, green, and red, 
respectively. Because the set of 22062 genes contains cell-type specific genes, the HCA 
clustered the cell type-dependent genes in the early and mid phases. 
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3-2: Identification of common gene expression patterns with 
distinct functions during reprogramming  
I clustered 3615 genes into five groups based on their expression patterns and 
performed functional annotations for each group.  
The first cluster contained 816 genes that were more highly expressed in the early phase 
and remained suppressed throughout the reprogramming process (Figure 3a). These 
genes were mainly annotated as playing a role in extracellular matrix organization, 
which could directly influence cell proliferation and differentiation (Hynes, 2009). 
Specifically, the cluster included TGF-β family members (TGFB1, TGFB1I1, TGFB2, 
TGFB3, TGFBI, TGFBR2, TGFBR3), and TGF-β-induced EMT markers (ZEB1, 
SNAI2, and TWIST2). These genes have been reported to be negative regulators of 
MET and are down-regulated by induction of exogenous Sox2, Oct4, and c-Myc during 
MEF reprogramming (Li et al., 2010; Maherali and Hochedlinger, 2009). Thus, the 
results suggest that reprogramming cells between days 0 and 3 are preparing for MET, a 
prerequisite for the commencement of reprogramming and one of the hallmarks of 
initiation, by inhibiting EMT pathways (Golipour et al., 2012). 
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The second cluster included 536 genes that were highly expressed during the early and 
mid phases but whose expression decreased in the late phase (Figure 3b). This cluster 
was annotated as immune response-related genes, which might be caused by the 
retroviral induction system used for exogenous OSKM expression. Because OSKM 
transgenes were sustainably expressed by day 15 (Takahashi et al., 2014), and the 
retroviral gene induction system is known to trigger an innate immune response (Jolly, 
2011), maintained retrovirus might contribute to increased immune function in the early 
and mid phases of reprogramming. Notably, suppression of the immune response by 
supplementation with inhibitors of either B18R interferon or NFkB enhanced hiPSC 
generation (Soria-Valles et al., 2015; Warren et al., 2010), indicating an inverse 
correlation between the immune system and reprogramming efficiency. Therefore, 
considering that the interferon-induced IFIT protein family was enriched in the early 
phase from the first gene cluster analysis (Figure 3a), innate immune-related genes in 
the first and second clusters may play an inhibitory role in cellular reprogramming, 
especially when a retrovirus induction system is used.  
The 394 genes in the third cluster had transiently up-regulated expression only in the 
mid phase. These genes were enriched for hemidesmosome and epidermal 
development-related genes (Figure. 3c). The 394 genes included epidermis-related 
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genes, such as SFN and KRT6A. A previous report demonstrated that these epidermal-
related genes were transiently up-regulated during the reprogramming of MEFs into 
iPSCs (O’Malley et al., 2013). Given that the inhibition of these genes precedes the 
activation of pluripotency genes in the late phase (O’Malley et al., 2013), the transitory 
expression of epidermis-related genes could be an important feature of the mid phase in 
both mice and humans.  
The expression of the 929 genes in the fourth cluster was sharply up-regulated in the 
late phase of reprogramming and these genes were annotated as trans-synaptic signaling 
related genes (Figure. 3d). Interestingly, previous studies reported that human and 
mouse neuronal stem cells (NSCs) could be reprogrammed by induction of OCT4 alone 
because NSCs endogenously expresses Sox2, Klf4, and c-Myc (Kim et al., 2009a, 
2009b), indicating a higher reprogramming efficiency in trans-synaptic enriched cell 
types. Given that tissue-derived human neuronal progenitor cells were more closely 
related to ESCs/iPSCs compared with other tissue-derived cells (Figure. 3g, f), it can be 
speculated that NSCs would share similar gene profiles to the late phase of human 
reprogramming cells. 
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The genes in the fifth cluster gradually increased as reprogramming progressed (Figure 
3e). They were highly enriched for cell cycle related genes, had especially dense 
protein-protein interactions and contained members of the Cyclin (CCNA2, CCNB1, 
CCNB2, CCND2, CCNE1, CCNI2) and CDK (CDK1, CDK18, CDKN3) families. This 
is in agreement with a previous study that showed that hES/hiPS cells require high 
proliferation rates for the acquisition and maintenance of pluripotency and self-renewal 
(Ruiz et al., 2011). In addition, this result may indicate the possibility of selection 
during reprogramming. In other words, a certain cell population that acquires high 
proliferative ability might survive in the early and/or mid phase and might eventually 
become dominant in the late phase. 
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Figure. 3a: 816 genes with high expression in the early phase, including MET-
related genes 
The upper panel shows gene expression profiles in the cluster. The colors indicate 
different cell types. The middle panel is the result of gene enrichment analysis. GO and 
R-HSA indicate Gene Ontology and Reactome (Homo sapiens), respectively. The lower 
panel illustrates protein-protein interactions. 
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Figure. 3b: 536 genes with high expression in the early and mid phases, including 
innate immune response related genes. 
The upper panel shows gene expression profiles in the cluster. The colors indicate 
different cell types. The middle panel is the result of gene enrichment analysis. GO and 
R-HSA indicate Gene Ontology and Reactome (Homo sapiens), respectively. The lower 
panel illustrates protein-protein interactions. 
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Figure. 3c: 394 genes with transient up-regulation in the mid phase were enriched 
for epidermis and hemidesmosome-related genes 
The upper panel shows gene expression profiles in the cluster. The colors indicate 
different cell types. The middle panel is the result of gene enrichment analysis. GO, ko, 
and R-HSA indicate Gene Ontology, KEGG Pathway (Homo sapiens), and Reactome 
(Homo sapiens), respectively. The lower panel illustrates protein-protein interactions. 
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Figure. 3d: 929 genes with sharp up-regulation in the late phase, including trans-
synaptic signaling related genes 
The upper panel shows gene expression profiles in the cluster. The colors indicate 
different cell types. The middle panel is the result of gene enrichment analysis. GO 
indicates Gene Ontology. The lower panel illustrates protein-protein interactions. 
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Figure. 3e: 940 genes displaying a gradual increase in expression, including cell 
cycle related genes 
The upper panel shows gene expression profiles in the cluster. The colors indicate 
different cell types. The middle panel is the result of gene enrichment analysis. GO, hsa, 
and R-HSA indicate Gene Ontology, KEGG Pathway (Homo sapiens), and Reactome 
(Homo sapiens), respectively. The lower panel illustrates protein-protein interactions. 
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Figure. 3f: Principal component analysis of 75 samples in 3615 genes indicated the 
transcriptional similarities between neural progenitor cells (NPC) and the late 
phase 
PCA using 3615 dynamically expressed genes. Tissue-derived cells and ESC-derived 
cells are labeled in black and dark red, respectively.  
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Figure. 3g: Principal component analysis of 75 samples and all 22062 genes also 
indicated the transcriptional similarities between neural progenitor cells (NPC) 
and the late phase 
PCA using all 22062 genes in the GPL14550 platform. Tissue-derived cells and ESC-
derived cells are labeled in black and dark red, respectively.  
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3-3: TF influence drastically changes between the mid phase 
and the late phase 
Because TFs play a critical role in regulating cell fate by controlling downstream gene 
expression, I investigated candidate TFs that could play important roles in each 
reprogramming phase. For this purpose, I scored TF influences and constructed a TF 
network. I extracted 71 TFs that could have a major influence and displayed their 
influences in different colors. The heatmap of TF influences clearly showed two distinct 
clusters. The pluripotency-related TFs, including NANOG, SALL4, endogenous 
POU5F1 and endogenous SOX2, had a positive influence value in the late phase 
(Figure. 4a). On the other hand, tissue morphogenesis-associated TFs, such as EHF, 
MEF2C, and FOXE1, had positive influence values in the early phase (Figure. 4a). 
Next, I visualized the co-regulatory network, including all 71 TFs for each time point in 
the reprogramming process. The time-course TF network illustrated that the TFs with 
positive influence values between days 0 and 15 had a sparse network compared to the 
TFs with negative influence values, whereas the TFs with positive influence values 
beginning at day 20 had a denser network than the TFs with negative influence values 
beginning at day 20. This result reflects the heterogeneity in cell status across different 
phases (Figure. 4b). Furthermore, no co-regulatory networks were observed between the 
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mid phase and the late phase (Figure. 4b). Thus, the transition in TF influence suggested 
that a major transcriptome transition might occur between days 15 and 20.  
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Figure. 4a: Heatmap of TF influences suggested a dynamic transition in TF 
influence between the mid and late phases 
The X-axis shows each sample during reprogramming and the Y-axis indicates the 71 
transcription factors that were inferred to have high influences on the overall gene 
expression patterns. The TF influence was defined as the t-statistic of gene expressions 
positively and negatively correlated with the TF and its score is indicated by color (red: 
positive, blue: negative). 
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Figure. 4b: No TF networks can be found between the mid and late phases, which 
indicates distinct TF activity in the late phase 
Inferred co-regulatory TF networks during the reprogramming process at days 0, 15, 
and 20 after OSKM induction. The TF influence scores are indicated by color (red: 
positive, blue: negative). The gray line shows the edge of the co-operative TF network.  
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Chapter 4: Discussion 
4-1: Maturation might be the roadblock in the 
reprogramming of various somatic cell types into hiPSCs 
In this study, I analyzed 3615 extracted genes from five human cell types with dynamic 
expression during the reprogramming process (Figure 1a, b) to determine whether a 
shared reprogramming route could be observed in human cellular reprogramming. The 
results of the transcriptome analysis indicated that a common route of reprogramming in 
human somatic cells could be divided into three conserved clusters: an early phase, a 
mid phase and a late phase (Figure. 2a, b). The similarity of cellular states obtained 
using transcriptomic data from the extracted dynamically expressed genes showed three 
clusters. In particular, a major dissimilarity was observed between the mid phase and 
the late phase (Figure. 2a, b). Moreover, I functionally annotated the groups of genes 
clustered by their gene expression patterns (Figure. 3a-e). Finally, I studied TF activity 
and reconstructed TF networks; this analysis revealed that the major difference in TF 
activity occurred during the transition between the mid phase and the late phase (Figure. 
4a, b).  
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Recent studies indicate that maturation, which is characterized as the phase when 
pluripotency genes, including Nanog, Sall4, and Oct4, start to be expressed (David and 
Polo, 2014; Samavarchi-Tehrani et al., 2010), is the major roadblock in the process of 
reprogramming HDFs into hiPSCs (Tanabe et al., 2013). The study demonstrated that, 
although approximately 20% of retrovirus-infected cells at day 7 of OSKM induction 
express TRA-1-60, a pluripotent stem cell surface marker, only a small portion of the 
TRA-1-60 positive cells become iPSCs. This may be because many intermediate cells 
revert back to TRA-1-60 negative cells (Tanabe et al., 2013). In our study, NANOG 
expression gradually increased and reached a plateau during the mid phase (Figure. 1b). 
This indicated that the mid phase might correspond to the maturation phase. Therefore, 
our results indicated that the maturation phase could be the major roadblock in various 
human cell types (Figure. 2a, b and Figure. 4a, b).  
Notably, the transcriptome and TF activity in epithelial cells exhibited distinct 
differences between the mid phase (days 7 to 15) and the late phase (day 20 to hiPSC 
establishment), corresponding to the maturation and stabilization phases (Figure. 2a, b 
and Figure. 4a, b), even though epithelial cells do not require MET for initiation. 
Therefore, studying the underlying mechanisms of maturation in more detail is 
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important and could lead to improved clinical availability of various human tissue-
derived cells.  
4-2: Comparison of the results with previous studies 
Our study indicated that the downregulation of TFs with positive influence values in the 
early and mid phases might hold the key to overcoming the roadblock of the maturation 
phase. For instance, a recent study reported that co-expression of FOSL2 with OSKM 
had an inhibitory effect on the reprogramming of both of human corneal epithelial cells 
(CECs) and HDFs (Kitazawa et al., 2016). Correspondingly, our study showed that the 
expression and influence of FOSL2 remained up-regulated in the early and mid phases 
in both mesenchymal cells and epithelial cells but was negatively regulated in the late 
phase (Figure. 4a, b, and Figure. 5a). This supports the hypothesis that inhibition of 
Fosl2 expression might drive reprogramming towards the maturation phase. 
Interestingly, AP-1 complexes, such as c-Jun and c-Fos, were reported to reduce the 
reprogramming efficiency in MEFs by impeding MET at initiation (Liu et al., 2015). 
However, our results suggested that FOSL2 might also play a suppressive role in the 
maturation phase of reprogramming.  
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In addition, DNMT3L, a catalytically inactive DNA methyltransferase regulatory factor, 
was reported to be highly expressed on day 20 of the reprogramming of HDFs into 
iPSCs (Cacchiarelli et al., 2015). Moreover, DNMT3L-overexpressing HeLa cells 
exhibited iPSC-like colonies and high SOX2 expression levels, even after over 20 
passages (Gokul et al., 2009). However, to the best of our knowledge, the functional 
role of DNMT3L has not yet been studied in the context of cellular reprogramming. 
Surprisingly, in our study, DNMT3L expression was transiently up-regulated in the mid 
phase (Figure. 4a, b, and Figure 5b), indicating that DNMT3L may play some biological 
role in the facilitation of maturation during reprogramming. Moreover, AIRE had a 
similar expression and influence profile to DNMT3L; its expression and influence value 
were only positive in the mid phase (Figure. 4a, b, and Figure 5b). Given that the 
genomic locations of DNMT3L and AIRE are closely coordinated on human 
chromosome 21 and given that they share their 23.5 kb upstream region, it may be 
speculated that DNMT3L and AIRE may be regulated by the same mechanisms, such as 
by other TFs or by epigenetic modification.  
4-3: Comparison of the reprogramming processes in mice and 
humans 
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The previous studies illustrated the reprogramming of mouse cell lines from MEFs. In 
these studies, first mesenchymal gene expression was lost, followed by transient 
upregulation of epidermal genes, and finally the stable expression of pluripotency-
related genes (O’Malley et al., 2013; Ruetz and Kaji, 2014). Interestingly, our analysis 
of human cellular reprogramming was partially consistent with the mouse 
reprogramming gene expression patterns (Figure. 3a, c, e). Specifically, the TF network 
suggested that epidermis-related TFs, such as KLF4 and EHF, had a cooperative 
interaction and changed from positive to negative influence values in the late phase 
(Figure 4b). Several studies reported the significance of Klf4 in reprogramming 
efficiency; low Klf4 protein levels paused the reprogramming process in MEFs 
regardless of high expression of the other reprogramming factors (Oct4, Sox2 and c-
Myc) (Nishimura et al., 2014); further, the length of Klf4 isoforms was critical for the 
determination of reprogramming efficiency (Chantzoura et al., 2015; Kim et al., 2015). 
Therefore, KLF4 and its co-operative genes may play important roles in the transition to 
the late phase by overcoming the roadblock of reprogramming maturation. Furthermore, 
the transient upregulation of epidermal-related genes in human cells supports the 
possibility that the reprogramming process is not simply the opposite of normal 
development (O’Malley et al., 2013). 
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4-4: A possible population selection in maturation 
Although transcriptome dynamics during reprogramming were justifiably represented 
using a microarray dataset, the bulk nature of microarray measurements of cell 
populations can mask the transcriptomic changes of small cell populations (Saliba et al., 
2014). Nevertheless, this study consistently revealed that the expression of cell cycle-
related genes gradually increased from the early phase to the late phase (Figure. 3e) and 
that the TF influence drastically changed between the mid phase and the late phase 
(Figure. 4a). In addition, the high density of TF networks displaying a shift in influence 
from negative to positive suggested a homogenous co-operative TF activity (Figure. 
4b), strengthening the possibility that a masked population could represent cellular 
reprogramming. Given that the reprogramming cells acquire high proliferative ability at 
the early phase (Ruiz et al., 2011), these results indicated that only a small subset of 
cells that acquired pluripotency and high proliferative ability in the mid phase could 
survive and continue to proliferate in self-replicative manner, eventually dominating the 
late phase population. To address this issue accurately, single-cell RNA sequence at the 
mid phase would be required.  
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As far as I know, our report is the first study to show that the human reprogramming 
process is partially shared across multiple different human somatic cell types and that 
maturation could be a common barrier in the reprogramming of various human cell 
types. This strategy could be applied not only to transcriptomic but also to epigenetic or 
proteomic studies and would provide further insights into the fundamental mechanisms 
of cellular reprogramming. 
In conclusion, I demonstrated that the reprogramming process is shared across five 
human somatic cell types by applying genome-wide analyses of time-course microarray 
data. From the results of functional annotations of gene expression patterns and 
reconstruction of transcription factor activity, I suggest that the maturation phase could 
be the common roadblock in the reprogramming of various cell types into hiPSCs. 
Identification of a reprogramming route that is shared across cell types would provide 
critical insight into the mechanisms of cellular reprogramming. 
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Figure. 5a: Expression pattern of FOSL2  
'A_23_P348121' indicates the FOSL2 Probe ID in the GPL14550 microarray platform.  
60 
 
 
 
Figure. 5b: Expression patterns of DNMT3L and AIRE during reprogramming  
'A_23_P17673' and 'A_23_P68740' indicate Probe IDs in the GPL14550 microarray 
platform.  
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